These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 18481498)

  • 1. Use of rFVIIa in the trauma setting--practice patterns in United States trauma centers.
    Horton JD; DeZee KJ; Wagner M
    Am Surg; 2008 May; 74(5):413-7. PubMed ID: 18481498
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant activated coagulation factor VII and bleeding trauma patients.
    Rizoli SB; Nascimento B; Osman F; Netto FS; Kiss A; Callum J; Brenneman FD; Tremblay L; Tien HC
    J Trauma; 2006 Dec; 61(6):1419-25. PubMed ID: 17159685
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The effects of acidosis and hypothermia on blood transfusion requirements following factor VII administration.
    Hall K; Forrest P; Sawyer C
    Anaesth Intensive Care; 2007 Aug; 35(4):494-7. PubMed ID: 18020065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Recombinant activated factor VII: a solution to refractory haemorrhage in vascular surgery?
    Warren OJ; Alcock EM; Choong AM; Leff DR; Van Herzeele I; Darzi AW; Athanasiou T; Cheshire NJ
    Eur J Vasc Endovasc Surg; 2008 Feb; 35(2):145-52. PubMed ID: 17964194
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of recombinant factor VILa in Operation Iraqi Freedom and Operation Enduring Freedom: survey of Army surgeons.
    Kembro RJ; Horton JD; Wagner M
    Mil Med; 2008 Nov; 173(11):1057-9. PubMed ID: 19055178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Early versus late recombinant factor VIIa in combat trauma patients requiring massive transfusion.
    Perkins JG; Schreiber MA; Wade CE; Holcomb JB
    J Trauma; 2007 May; 62(5):1095-9; discussion 1099-101. PubMed ID: 17495707
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Current evidence based guidelines for factor VIIa use in trauma: the good, the bad, and the ugly.
    Duchesne JC; Mathew KA; Marr AB; Pinsky MR; Barbeau JM; McSwain NE
    Am Surg; 2008 Dec; 74(12):1159-65. PubMed ID: 19097529
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recombinant factor VIIa for the prevention and treatment of bleeding in patients without haemophilia.
    Simpson E; Lin Y; Stanworth S; Birchall J; Doree C; Hyde C
    Cochrane Database Syst Rev; 2012 Mar; (3):CD005011. PubMed ID: 22419303
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Trauma, transfusions, and use of recombinant factor VIIa: A multicenter case registry report of 380 patients from the Western Trauma Association.
    Knudson MM; Cohen MJ; Reidy R; Jaeger S; Bacchetti P; Jin C; Wade CE; Holcomb JB
    J Am Coll Surg; 2011 Jan; 212(1):87-95. PubMed ID: 21115374
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Off-label use of recombinant factor VIIa in two tertiary hospitals in Queensland.
    Donovan PJ; Iedema J; McLeod DS; Kubler P; Pillans P
    ANZ J Surg; 2013 Mar; 83(3):149-54. PubMed ID: 23137066
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Patient/caregiver-reported recombinant factor VIIa (rFVIIa) dosing: home treatment of acute bleeds in the Dosing Observational Study in Hemophilia (DOSE).
    Young G; Shapiro AD; Walsh CE; Gruppo RA; Gut RZ; Cooper DL
    Haemophilia; 2012 May; 18(3):392-9. PubMed ID: 22171621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The use of recombinant activated factor VII for blood loss after cardiovascular surgery].
    Gong ZY; Gao CQ; Xiao CS; Li BJ; Ma XH; Zhang CM
    Zhonghua Wai Ke Za Zhi; 2008 Oct; 46(19):1497-501. PubMed ID: 19094631
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Off-label use of recombinant factor VII (rFVIIa) in teaching hospitals in Paris in 2010].
    Bardon J; Fink J; de Montblanc J; Bergmann JF; Sarrut B; Benhamou D
    Ann Fr Anesth Reanim; 2013 Oct; 32(10):659-64. PubMed ID: 23953834
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The use of recombinant activated factor VII (rFVIIa) in the management of patients with major haemorrhage in military hospitals over the last 5 years.
    Smith JE
    Emerg Med J; 2013 Apr; 30(4):316-9. PubMed ID: 22609697
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of recombinant factor VIIa as an adjunctive therapy in damage control for wartime vascular injuries: a case control study.
    Fox CJ; Mehta SG; Cox ED; Kragh JF; Salinas J; Holcomb JB
    J Trauma; 2009 Apr; 66(4 Suppl):S112-9. PubMed ID: 19359954
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant factor VIIa in trauma patients with the 'triad of death'.
    Mitra B; Cameron PA; Parr MJ; Phillips L
    Injury; 2012 Sep; 43(9):1409-14. PubMed ID: 21345431
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of recombinant factor VIIa in US military casualties for a five-year period.
    Wade CE; Eastridge BJ; Jones JA; West SA; Spinella PC; Perkins JG; Dubick MA; Blackbourne LH; Holcomb JB
    J Trauma; 2010 Aug; 69(2):353-9. PubMed ID: 20699744
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The incidence of thromboembolism formation following the use of recombinant factor VIIa in patients suffering from blunt force trauma compared with penetrating trauma: a systematic review.
    Devlin R; Bonanno L; Badeaux J
    JBI Database System Rev Implement Rep; 2016 Mar; 14(3):116-38. PubMed ID: 27532142
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recombinant factor VIIa (NovoSeven RT) use in high risk cardiac surgery.
    Chapman AJ; Blount AL; Davis AT; Hooker RL
    Eur J Cardiothorac Surg; 2011 Dec; 40(6):1314-8; discussion 1318-9. PubMed ID: 21601468
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Timing of factor VIIa in liver transplantation impacts cost and clinical outcomes.
    Scheffert JL; Taber DJ; Pilch NA; McGillicuddy JW; Baliga PK; Chavin KD
    Pharmacotherapy; 2013 May; 33(5):483-8. PubMed ID: 23468226
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.